- Capital Cube•17 hours ago
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Merck KGaA a score of 47. Our analysis is based on comparing Merck KGaA with the following peers – Eli Lilly and Company, AbbVie, Inc., Pfizer Inc. and Lannett Company, Inc. (LLY-US, ABBV-US, PFE-US and LCI-US). Investment Outlook Merck KGaA has a fundamental score of 47 and ... Read more (Read more...)
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars unit of German peer Merck KGaA.
German healthcare group Fresenius SE & Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA. Takeovers were part of Fresenius's growth strategy under previous boss Ulf Mark Schneider, now leading Nestle. The latest deals are in keeping with Fresenius's focus on drugs that have lost patent protection, but also mark a foray into new dosage forms, therapeutic areas and biotech drugs for its Kabi unit, a maker of generic infusion drugs as well as tube feeding and blood transfusion equipment.
MKGAF: Summary for MERCK KGAA DM 5 - Yahoo Finance
Merck Kommanditgesellschaft auf Aktien (MKGAF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
|Day's range||0.00 - 0.00|
Trade prices are not sourced from all markets
|PE ratio (TTM)||29.48|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|